Inogen, Inc (INGN) EVP Matt Scribner Sells 2,500 Shares
Inogen, Inc (NASDAQ:INGN) EVP Matt Scribner sold 2,500 shares of the firm’s stock in a transaction on Thursday, December 14th. The stock was sold at an average price of $120.34, for a total value of $300,850.00. Following the sale, the executive vice president now owns 7,297 shares in the company, valued at approximately $878,120.98. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Matt Scribner also recently made the following trade(s):
- On Monday, November 13th, Matt Scribner sold 2,500 shares of Inogen stock. The stock was sold at an average price of $112.35, for a total value of $280,875.00.
- On Thursday, October 12th, Matt Scribner sold 2,500 shares of Inogen stock. The stock was sold at an average price of $93.88, for a total value of $234,700.00.
Shares of Inogen, Inc (NASDAQ:INGN) traded up $2.63 during trading on Friday, reaching $122.12. The company had a trading volume of 409,485 shares, compared to its average volume of 171,565. Inogen, Inc has a 52-week low of $62.69 and a 52-week high of $130.05. The firm has a market capitalization of $2,529.91, a PE ratio of 98.55, a P/E/G ratio of 5.09 and a beta of 1.13.
A number of institutional investors have recently modified their holdings of INGN. Teachers Advisors LLC increased its holdings in shares of Inogen by 2.8% in the first quarter. Teachers Advisors LLC now owns 27,790 shares of the medical technology company’s stock valued at $2,155,000 after buying an additional 749 shares in the last quarter. Aperio Group LLC acquired a new stake in Inogen during the 2nd quarter valued at $854,000. Municipal Employees Retirement System of Michigan raised its stake in Inogen by 4.4% during the 2nd quarter. Municipal Employees Retirement System of Michigan now owns 3,820 shares of the medical technology company’s stock valued at $365,000 after purchasing an additional 160 shares during the period. Texas Permanent School Fund raised its stake in Inogen by 1.4% during the 2nd quarter. Texas Permanent School Fund now owns 11,871 shares of the medical technology company’s stock valued at $1,133,000 after purchasing an additional 159 shares during the period. Finally, Sei Investments Co. raised its stake in Inogen by 38.1% during the 2nd quarter. Sei Investments Co. now owns 1,606 shares of the medical technology company’s stock valued at $153,000 after purchasing an additional 443 shares during the period.
Several equities research analysts have recently issued reports on the company. BidaskClub cut Inogen from a “buy” rating to a “hold” rating in a report on Tuesday, December 5th. Needham & Company LLC raised their price objective on Inogen from $108.00 to $125.00 and gave the stock a “strong-buy” rating in a report on Wednesday, November 8th. Zacks Investment Research upgraded Inogen from a “hold” rating to a “buy” rating and set a $131.00 price objective on the stock in a report on Thursday, November 9th. Piper Jaffray Companies restated a “hold” rating and set a $90.00 price objective on shares of Inogen in a report on Tuesday, September 12th. Finally, Leerink Swann restated an “outperform” rating and set a $120.00 price objective (up previously from $115.00) on shares of Inogen in a report on Wednesday, November 8th. Four research analysts have rated the stock with a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the company. The company has an average rating of “Buy” and an average target price of $103.14.
TRADEMARK VIOLATION NOTICE: This story was posted by American Banking News and is the sole property of of American Banking News. If you are accessing this story on another publication, it was copied illegally and republished in violation of U.S. & international trademark & copyright legislation. The legal version of this story can be accessed at https://www.americanbankingnews.com/2017/12/15/inogen-inc-ingn-evp-matt-scribner-sells-2500-shares.html.
Inogen Company Profile
Inogen, Inc is a medical technology company. The Company develops, manufactures and markets portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. The Company’s Inogen One systems concentrate the air around the patient to offer a single source of supplemental oxygen anytime, anywhere with a portable device.
Receive News & Ratings for Inogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inogen and related companies with MarketBeat.com's FREE daily email newsletter.